Literature DB >> 23731630

Bordetella pertussis iron regulated proteins as potential vaccine components.

Jimena Alvarez Hayes1, Esteban Erben, Yanina Lamberti, Guido Principi, Fabricio Maschi, Miguel Ayala, Maria Eugenia Rodriguez.   

Abstract

Bordetella pertussis is the etiologic agent of whooping cough, an illness whose incidence has been increasing over the last decades. Pertussis reemergence despite high vaccination coverage, together with the recent isolation of circulating strains deficient in some of the vaccine antigens, highlight the need for new vaccines. Proteins induced under physiological conditions, such as those required for nutrient acquisition during infection, might represent good targets for better preventive strategies. By mean of serological proteome analysis we identified two novel antigens of B. pertussis potentially involved in iron acquisition during host colonization. We had previously demonstrated that one of them, designated IRP1-3, is protective against pertussis infection in mice. In the present study, we show that the other antigen, named AfuA (BP1605), is a highly antigenic protein, exposed on the bacterial surface, conserved among clinical isolates and expressed during infection. Immunization of mice with the recombinant AfuA induced opsonophagocytic antibodies which could explain the protection against B. pertussis infection conferred by mice immunization with rAfuA. Importantly, we found that the addition of rAfuA and rIRP1-3 proteins to the commercial three pertussis components acellular vaccine significantly increased its protective activity. Taken together, our results point at these two antigens as potential components of a new generation of acellular vaccines.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bordetella pertussis; New antigens; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 23731630     DOI: 10.1016/j.vaccine.2013.05.072

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

Review 2.  Development of improved pertussis vaccine.

Authors:  Martin Rumbo; Daniela Hozbor
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

4.  Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.

Authors:  Dylan T Boehm; Jesse M Hall; Ting Y Wong; Andrea M DiVenere; Emel Sen-Kilic; Justin R Bevere; Shelby D Bradford; Catherine B Blackwood; Cody M Elkins; Katherine A DeRoos; Mary C Gray; C Garret Cooper; Melinda E Varney; Jennifer A Maynard; Erik L Hewlett; Mariette Barbier; F Heath Damron
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

5.  Quantitative proteomic analysis of Shigella flexneri and Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) reveals highly pure preparations.

Authors:  Luana Maggiore; Lu Yu; Ulrich Omasits; Omar Rossi; Gordon Dougan; Nicholas R Thomson; Allan Saul; Jyoti S Choudhary; Christiane Gerke
Journal:  Int J Med Microbiol       Date:  2015-12-23       Impact factor: 3.473

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.